Exacis Biotherapeutics Develops mRNA-Engineered iPSC-Derived NK Cells For Difficult-To-Treat Tumors
Exacis has generated NK cells from iPSCs engineered using mRNA gene-editing technology to resist rejection by the patient’s immune system.
Exacis has generated NK cells from iPSCs engineered using mRNA gene-editing technology to resist rejection by the patient’s immune system.